What if the complex journey of turning a groundbreaking biologic into a life-saving therapy could be transformed into a streamlined, efficient process? In a world where biopharmaceutical development faces unprecedented challenges, a powerful collaboration between Rentschler Biopharma and Coriolis
Imagine a simple shot, one already familiar to millions for preventing a painful skin condition, holding the power to shield the mind from a devastating disease like dementia—a condition impacting over 55 million people worldwide with no cure in sight. That’s the startling promise emerging from a
Diving into the complex world of microbiome research, I had the privilege of speaking with Ivan Kairatov, a renowned biopharma expert with extensive experience in technology and innovation within the industry. With a strong background in research and development, Ivan has been instrumental in
Imagine a world where life-altering therapies for genetic disorders, cancer, and infectious diseases are not just a distant dream but a tangible reality, delivered precisely to the cells that need them most. RNA therapeutics hold this transformative promise, yet their potential remains locked
Ivan Kairatov has spent years at the crossroads of oncology and drug development, translating trial signals into day-to-day decisions for patients with localized prostate cancer. In this conversation, he unpacks new evidence showing that most of the value from androgen deprivation therapy (ADT)
A therapy that should unleash the immune system instead fuels a tumor’s growth, and the only way to see why is to listen to each cell speak for itself; that is the everyday paradox that single-cell RNA sequencing (scRNA-seq) now makes decipherable in real time. In oncology, this shift from average
